|Bid||128.00 x 100|
|Ask||143.35 x 100|
|Day's Range||130.00 - 132.51|
|52 Week Range||92.65 - 143.37|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||154.00|
Analysts are bullish on these following companies: GW Pharmaceuticals, Geron, SmartFinancial. These companies are relatively strong financially, and have a great outlook in terms of profits and cash flow. IfRead More...
LONDON and CARLSBAD, Calif., Feb. 06, 2018-- GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid ...
NEW YORK, NY / ACCESSWIRE / February 6, 2018 / The markets recent selloff continued Monday as a result of rising interest rates. Both the Dow Jones and the S&P 500 fell sharply to close in negative territory ...
ADR (NASDAQ:GWPH) has garnered approval for the review of a new medication to treat seizure patients. The European Medicines Agency (EMA) has accepted the biopharmaceutical’s request to review the Market Authorization Application (MAA) of Epidiolex, or cannibidiol. The medication is used to treat patients who suffer from seizures linked to Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
LONDON and CARLSBAD, Calif., Feb. 05, 2018-- GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from its proprietary cannabinoid ...
-Epidiolex ® NDA and MAA applications accepted for review–- NDA PDUFA goal date scheduled for June 27, 2018-- Conference call today at 4:30 p.m. EST-. LONDON and CARLSBAD, Calif., Feb. 05, 2018-- GW Pharmaceuticals ...
In this article we are going to present an alternative to weed stocks such as GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), Cara Therapeutics Inc (NASDAQ:CARA), Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP), and Insys Therapeutics Inc (NASDAQ:INSY). When it comes to investing in the marijuana industry many people think about stocks of companies that are either growing and/or selling […]
NEW YORK, NY / ACCESSWIRE / February 2, 2018 / Rising bond yields created mixed results on Wall Street Thursday. The S&P 500 Index declined 0.06 percent to close at 2,821.98, while the Nasdaq Composite ...
GW Pharma (GWPH) will report fiscal first-quarter results next week. Investors focus is expected to be on the Epidiolex commercialization plan.
Scotts Miracle-Gro missed Q1 views and said "slower-than-expected pace of regulatory changes in California" were harming its hydroponics business.
LONDON, Jan. 29, 2018-- GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, ...
–First well-controlled clinical study of cannabidiol in Lennox-Gastaut syndrome, a rare, severe, form of childhood-onset epilepsy that is difficult to treat–. –Pharmaceutical formulation of cannabidiol ...
2017 had a bullish tone, as assets across categories shone the brightest, although cryptocurrency could be singled out as the standout performer. Marijuana stocks also joined the party, as reflected by ...
Back in April, I talked about how GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) was one of the best plays on medical marijuana. Considering the way the cannabinoids work, it makes sense that the main application for medical marijuana would be for neurological disorders — something GWPH was quick to latch on to. GWPH stock has certainly had its trying times — falling on reports stating that medical cannabis could take a way billions of dollars in sales from the pharmaceutical industry for the different conditions it can treat, including epilepsy.
Australia earlier this month joined the growing list of nations that have legalized medical marijuana. The Marijuana Index is a series of equally weighted stock indexes that track the leading cannabis stocks in the U.S. and Canada. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), with a market cap of $3.34 billion, produces a multiple sclerosis treatment using nabiximols, an herbal preparation containing a defined quantity of specific cannabinoids with potential analgesic activity.
Yahoo Finance's Seana Smith, Andy Serwer, Ethan Wolff-Mann and Dion Rabouin discuss why now could be a good time to invest in marijuana stocks.